Literature DB >> 2431540

Antigenic mapping of the surface proteins of rhesus rotavirus.

R D Shaw, P T Vo, P A Offit, B S Coulson, H B Greenberg.   

Abstract

Monoclonal antibodies have been produced and used to map the functional topography of the surface proteins of rhesus rotavirus (RRV) that mediate viral neutralization. Ten monoclonal antibodies directed to VP7 were studied in neutralization assays and competitive binding studies. A large neutralization domain with several interrelated epitopes on VP7 was apparent. Twelve monoclonal antibodies directed to VP3 were used in similar studies and delineated at least 2 distinct neutralization domains on that protein. Neutralizing monoclonal antibodies directed at both VP3 and VP7 were used to isolate viral antigenic variants, which were than studied in neutralization and hemagglutination inhibition assays. The viral variant studies, while confirming the general conclusions obtained from the competitive binding studies, allowed the apparent distinction of two separate neutralization domains on VP7 and three on VP3. All VP7-specific monoclonal antibodies (mAb) mediated serotype-specific neutralization, but a VP3-specific mAb was identified that neutralized rotaviruses of three distinct serotypes. No alteration of viral virulence was apparent in studies of suckling mice orally inoculated with antigenic variant viruses selected with our panel of neutralizing VP3 or VP7-specific mAbs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431540     DOI: 10.1016/0042-6822(86)90205-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  116 in total

1.  Rotavirus spike protein VP4 is present at the plasma membrane and is associated with microtubules in infected cells.

Authors:  M Nejmeddine; G Trugnan; C Sapin; E Kohli; L Svensson; S Lopez; J Cohen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins.

Authors:  I N Gavrilovskaya; E J Brown; M H Ginsberg; E R Mackow
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site.

Authors:  Philip R Dormitzer; Zhen-Yu J Sun; Gerhard Wagner; Stephen C Harrison
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

4.  Receptor activity of rotavirus nonstructural glycoprotein NS28.

Authors:  K S Au; W K Chan; J W Burns; M K Estes
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  ATP is required for correct folding and disulfide bond formation of rotavirus VP7.

Authors:  A Mirazimi; L Svensson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Antibodies to rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting virion decapsidation.

Authors:  Juan Ernesto Ludert; Marie Christine Ruiz; Carlos Hidalgo; Ferdinando Liprandi
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Discrete domains within the rotavirus VP5* direct peripheral membrane association and membrane permeability.

Authors:  Nina E Golantsova; Elena E Gorbunova; Erich R Mackow
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Specific interactions between rotavirus outer capsid proteins VP4 and VP7 determine expression of a cross-reactive, neutralizing VP4-specific epitope.

Authors:  D Y Chen; M K Estes; R F Ramig
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Reactivity of VP4-specific monoclonal antibodies to a serotype 4 porcine rotavirus with distinct serotypes of human (symptomatic and asymptomatic) and animal rotaviruses.

Authors:  S Y Kang; L J Saif; K L Miller
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

10.  Bovine rotavirus type detection by neutralizing monoclonal antibodies.

Authors:  E Cornaglia; Y Elazhary; B Talbot
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.